UWUlla Wartiovaara-Kautto

Ulla Wartiovaara-Kautto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ulla Wartiovaara-Kautto has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease

    by Suvi P.M. Douglas, Ilse Kaaja, Ina I Ikonen, Laura Langohr, Jessica Koski, Marja Hakkarainen, Lotta Katainen, Gisela Barbany, Eva Hellstrom-Lindberg, Kirsi Jahnukainen, et al.

    ERCC6L2 disease (ED) is an inherited bone marrow failure (BMF) syndrome that progresses almost exclusively to erythroid, TP53-mutated myeloid malignancy, but the somatic evolution underlying the progression in patients is unknown. We characterized the genetic landscape of 29 ED patients with longitudinal sampling, integrating whole-genome and single-cell RNA sequencing, and compared the findings with Shwachman-Diamond syndrome (SDS), another TP53 mutation-prone disease, to define somatic evolution across disease stages. ED was defined by early, intense, and recurrent selection of TP53-mutant clones: TP53 mutations were more frequent, more often multiple, and showed steeper age-related expansion than in SDS; all TP53-negative ED patients were children. The burden of multiple TP53 mutations exceeded that of sporadic TP53-mutated myeloid neoplasia and was evident before malignancy. Missense mutations dominated the BMF phase, whereas non-missense mutations were seen in patients with malignancy, consistent with biallelic second hits, marking a stage-dependent shift in p53 inactivation. Beyond TP53, the landscape was strikingly restricted, with PPM1D as the only recurrent driver gene. Notably, despite the DNA-repair function of ERCC6L2, no ED-specific mutational signature emerged; but instead reflected age-associated processes. Malignant progression was accompanied by a complex karyotype, recurrent chromosome 5, 7, and 12p losses enriched in erythroid progenitors, and kataegis, consistent with branched, erythroid-predominant clonal evolution. Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation. As progression is driven predominantly by p53 and captured longitudinally from the earliest clones, ED offers a model of how TP53-mutated leukemia arises and evolves, with relevance beyond a rare syndrome.

  • Open Access

    Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman–Diamond syndrome

    by Laura Langohr, Ilse Kaaja, Suvi P. M. Douglas, Hanna Nebelung, Jessica Koski, Ina Ikonen, Lotta Katainen, Katri Maljanen, Marja Hakkarainen, Tuulia Räisänen, et al.

    ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to the accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single‐cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single‐cell TP53 genotyping. We identify disease‐associated erythroid dysregulation and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman–Diamond syndrome (SDS) to reveal shared and disease‐specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis, despite harboring distinct germline defects. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease‐specific pattern, ED shows aberrant erythroid priming with TP53 ‐driven differentiation arrest shaping progression toward erythroid leukemia. Thereby, we establish the first patient‐level single‐cell map of ED and provide a curated resource for future work on ED, SDS, and TP53 ‐driven leukemogenesis. Overall, our findings in pre‐malignant ED offer a window into early alterations leading to high‐risk leukemia.


  • Open Access

    Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease

    by Marja Hakkarainen, Flore Sicre de Fontbrune, Ilse Kaaja, Suvi Douglas, Jean-Hugues Dalle, Antonio Maria Risitano, Austin Kulasekararaj, Abdulrahman Alsultan, Corey Cutler, Vincent T. Ho, et al.

    The hallmark of ERCC6L2 disease (ED) is a highly penetrant progression from bone marrow failure to erythroid-predominant, TP53-mutated myeloid malignancy with a dismal prognosis. Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative option, but concerns exist regarding transplant-related toxicities (TRT) due to the underlying DNA repair defect. To the best of our knowledge, this is the first study to report a systematic analysis of HSCT in ED. We conducted a retrospective multicenter study involving 45 patients with ED who underwent HSCT in 2004-2024. The primary outcomes were overall survival (OS), TRT, and nonrelapse mortality (NRM). The 1-year and 3-year OS were 79% (95% confidence interval [CI], 66-91) and 54% (95% CI, 35-73), respectively. Previous history of excess blasts significantly predicted inferior survival (hazard ratio [HR], 6.8; 95% CI, 2.2-20.3; P< .001), with a median survival of 12 months (95% CI, 0-24). Grade 3 to 5 endothelial toxicities occurred in 27% of patients and were associated with higher NRM (HR, 7.7; 95% CI, 1.5-38.8; P = .016). The use of nontreosulfan-based myeloablative conditioning (MAC) regimens increased the risk of endothelial complications compared with reduced-intensity conditioning (RIC; HR, 4.9; 95% CI, 1.1-22.0; P = .040), whereas outcomes with treosulfan-based MAC were comparable to RIC. In summary, allogeneic HSCT is a viable curative strategy for ED when performed before transformation to an aggressive malignancy, for example myelodysplasia with excess blasts or acute myeloid leukemia. However, the elevated incidence of endothelial toxicity highlights the importance of optimizing conditioning intensity and enhancing peritransplant monitoring in this population.


  • Open Access

    Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study

    by Atte Nikkilä, Olli Lohi, Jonas Abrahamsson, Laimonas Griskevicius, Helene Hallböök, Ólafur Gísli Jónsson, Bendik Lund, Hanne Vibeke Marquart, Ulrik Overgaard, Katrin Palk, et al.


  • Late Diagnosis of NBEAL2-related Gray Platelet Syndrome in Finnish Siblings with Lifelong Thrombocytopenia

    by Doris Boeckelmann, Terhi Friman, Hannah Glonnegger, Ulla Wartiovaara-Kautto, Barbara Zieger

    In the case of familial thrombocytopenia, a congenital defect should be considered; however, in particular older patients who have had thrombocytopenia for a long time have often not yet been genetically analyzed using modern sequencing methods. Remarkably, sometimes they are still suspected of suffering from chronic immune thrombocytopenia until genetic testing reveals a congenital defect. We report on elderly Finnish siblings (both older than 60 years) with lifelong thrombocytopenia. The lifelong bleeding tendency in both the siblings was usually treated with tranexamic acid and platelet transfusions when necessary. In 2022, the older brother presented at the University Hospital in Helsinki because he had recently been suffering from gastrointestinal bleeding and also had mild pancytopenia. Because his sister lived abroad, the Finnish colleagues recommended that the sister should present to the University Hospital in Freiburg. Independent genetic testing of both the siblings using NGS identified the diagnosis of NBEAL2-associated gray platelet syndrome. The disease comprises macrothrombocytopenia and a reduction of α-granules in platelets, resulting in a grayish appearance of platelets on the blood smear. Patients usually suffer from a mild to moderate bleeding diathesis. Interestingly, during the last years a more syndromic character of the disease has been described: besides the platelet phenotype, the immune system can also be affected. In the course of the disease patients may develop pancytopenia, splenomegaly, and bone marrow fibrosis. Comprehensive diagnostics including molecular genetic analyses are particularly important to provide these patients with adequate care and treatment.

  • Open Access

    Distinct Stem Cell Identities Converge into Shared Erythroid Stress in ERCC6L2 Disease and Shwachman-Diamond Syndrome

    by Laura Langohr, Ilse Kaaja, Suvi Douglas, Hanna Nebelung, Jessica Koski, Ina Ikonen, Lotta Katainen, Katri Maljanen, Marja Hakkarainen, Tuulia Räisänen, et al.

    ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in ERCC6L2 . ED leads to accumulation of somatic TP53 mutations, myelodysplastic syndrome, and acute myeloid leukemia (AML) with erythroid predominance and poor prognosis. Given the global challenge of treating TP53 -mutated AML, ED provides a unique opportunity to study early events leading to high-risk leukemia. While ERCC6L2 is implicated in DNA replication and repair, the transcriptomic events underlying delayed erythropoiesis and leukemic progression remain largely undefined. To delineate these processes, we leverage bulk and single-cell transcriptomics of patient fibroblasts, bone marrow, and peripheral blood across disease stages, including single-cell TP53 genotyping. We identify disease-associated erythroid delay and ferroptotic stress emerging prior to TP53 mutation, highlighting an early vulnerability in ED leukemogenesis. We compare ED to Shwachman-Diamond syndrome (SDS) to reveal shared and disease-specific transcriptional programs. TP53 mutations in ED and SDS arise in hematopoietic stem and progenitor cells but do not independently drive changes in cell cycle or stress pathways during erythropoiesis. Both diseases converge in late erythropoiesis into a stress state characterized by ferroptotic signaling, G1 arrest, and BCL2L1 upregulation. As a disease-specific pattern, ED shows aberrant erythroid priming and a differentiation block in TP53 -mutated cells during leukemic transformation. Taken together, we provide the first single-cell analyses in ED, define stress responses shared with SDS, and aberrant erythroid priming with TP53 -driven differentiation arrest shaping progression toward erythroid leukemia. Our results give biological insights to guide therapy development aiming at intercepting disease evolution to treatment-refractory AML. Key points: ERCC6L2 disease patient cells engage maladaptive erythroid programs early in differentiation Cell cycle and ferroptotic stress signatures persist despite somatic TP53 mutations

  • Open Access

    Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT

    by Atte K. Lahtinen, Maarja Karu, Jessica R. Koski, Jarmo Ritari, Kati Hyvärinen, Satu Koskela, Julia Nihtilä, Jukka Partanen, Kim Vettenranta, Minna Koskenvuo, et al.


  • Open Access

    Pathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population

    by Jessica R. Koski, Laura Langohr, Tuulia Räisänen, Atte K. Lahtinen, Marja Hakkarainen, Caroline A. Heckman, Ulla Wartiovaara-Kautto, Esa Pitkänen, Outi Kilpivaara

    Background: The clinical significance of most germline variants in hematological malignancies (HMs) remains unknown. This presents a challenge in the clinical setting, as the inability to accurately detect pathogenic variants can influence therapeutic decisions. Population isolates have been shown to be beneficial in pathogenic variant discovery due to presence of rare deleterious variants in relatively high frequencies. Methods: We developed and applied PaVaDi, a computational pipeline that follows American College of Medical Genetics and Genomics (ACMG) guidelines, to evaluate the pathogenicity of germline variants in 511 HM patients from the Finnish founder population. We conducted an exome-wide burden analysis to assess the overall contribution of pathogenic variants to HMs and identified significant gene associations. We also examined genes previously associated with hematological diseases and DNA repair in more detail, and performed protein stability analyses to resolve variants of unknown significance (VUS). Results: The exome-wide burden analysis revealed potential pathogenic alleles in CUX2, RNPC3, and MFSD2A that have not previously been linked to HM predisposition. We also identified the largest series of CHEK2 variant carriers reported in hematological diseases, including pathogenic/likely pathogenic (P/LP) variants ( n =19), Ile200Thr ( i.e. , Ile157Thr) ( n =49), and other variants of uncertain significance ( n =3). CHEK2 variants were 1.7-fold enriched in patients compared to controls (13.9% vs 8.3%, p =2×10 −5 ). Strikingly, Ile200Thr was enriched over four-fold in acute lymphoblastic leukemia patients. Finally, protein structure stability analyses suggested novel MPO variants to be potentially highly deleterious. Conclusions: This study highlights the importance of germline testing in hematological malignancies and demonstrates the utility of population isolates for pathogenic variant discovery. Our findings identify a significant burden of deleterious variants in HM patients, particularly in CHEK2 , and underscore the potential of multi-disease joint analyses in revealing germline contributions to hematological diseases.

  • Open Access

    How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms

    by Panagiotis Baliakas, Bianca Tesi, Jörg Cammenga, Asbjørg Stray‐Pedersen, Kirsi Jahnukainen, Mette Klarskov Andersen, Helena Ågerstam, Maria Creignou, Ingunn Dybedal, Klas Raaschou‐Jensen, et al.

    Increasing recognition of germline DDX41 variants in patients with hematological malignancies prompted us to provide DDX41‐specific recommendations for diagnosis, surveillance, and treatment. Causative germline variants in the DDX41 predispose to the development of myeloid neoplasms (MNs), especially myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Almost 3%–5% of all patients with MDS or AML carry a pathogenic or likely pathogenic germline DDX41 variant, while half of them acquire a somatic second hit in the other allele. DDX41‐associated MNs exhibit unique clinical characteristics compared to other hematological malignancies with germline predisposition: MNs occur mostly at advanced age and follow an indolent clinical course. Male carriers are more prone to develop MDS or AML than females. DDX41‐associated MN is often hypoplastic, and the malignancy may be preceded by cytopenias.


  • Open Access

    The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia

    by Marja Hakkarainen, Ilse Kaaja, Suvi P. M. Douglas, Thomas J Vulliamy, Inderjeet Dokal, Jean Soulier, Lise Larcher, Régis Peffault de Latour, Thierry M Leblanc, Flore Sicre de Fontbrune, et al.

    Biallelic germline ERCC6L2 variants strongly predispose to bone marrow failure (BMF) and myeloid malignancies characterized by somatic TP53-mutated clones and erythroid predominance. We present a series of 52 subjects (35 families) with ERCC6L2 biallelic germline variants collected retrospectively in 11 centers globally, including follow-up of 1165 person-years. At initial investigations, 32 individuals were diagnosed with BMF and 15 with a hematological malignancy (HM). Subjects presented with 19 different variants across ERCC6L2, and we identified a founder mutation c.1424delT in the Finnish patients. The median age of subjects at baseline was 18 years (range 2-65). Changes in complete blood count (CBC) were mild despite severe bone marrow hypoplasia and somatic TP53 mutations, with no significant difference between subjects with or without (HM). Signs of a progressive disease were increasing TP53 variant allele frequency, dysplasia in megakaryocytes and/or erythroid lineage, and erythroid predominance in bone marrow morphology. The median age at onset of HM was 37.0 years (95% CI: 31.5-42.5; range 12-65). Overall survival (OS) at 3 years was 95% (95% CI: 85-100) and 19% (95% CI: 0-39) for patients with BMF and HM, respectively. Patients with myelodysplastic syndrome or acute myeloid leukemia with mutated TP53 undergoing hematopoietic stem cell transplantation had a poor outcome: 3-year OS is 28% (95% CI: 0-61). Our results demonstrate the importance of early recognition and active surveillance of patients with biallelic germline ERCC6L2 variants.